Skip to main content

Table 1 Patients characteristics

From: Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation

  Age/gender (m/f) Disease/− stage Stem cell source, HLA matching Donor type/age/ gender Conditioning regimen CMV, EBV status (R/D)
Pat 1 51/m MM/relapse after autologous Tx PB, 11/12 MUD/22/ m Flu/Tre/ATG +/−, +/+
Pat 2 37/m Sezary’s syndrome PB, full MRD/47/m Cy/TBI +/−, +/+
Pat 3 35/f hrAML PB, full MUD/20/f Flu/Bu4/ATG +/+, +, n.d.
Pat 4 46/m hrAML PB, 8/8 MUD/29/f Flu/Bu4/ATG +/−, +/+
Pat 5 21/m preB-ALL, CR2 PB, 7/8 MUD/43/m Cy/TBI/ATG +/−, +/+
Pat 6 63/m MDS, RAEB 1 PB, full MRD/59/m FluTre −/−, +/+
Pat 7 68/m AML, IR PB, 8/8 MUD/34/m Flu/Bu2/ATG +/+, −/n.d.
Pat 8 59/f Post-ET myelofibrosis PB, 11/12 MUD/23/m Flu/Bu3/ATG +/+, +/+
Pat 9 27/f hrMDS PB, full MUD/38/m Flu/Tre/ATG +/−, +, n.d.
Pat 10 69/m MDS/AML PB, 10/12 MUD/37/m FluBu2ATG +/−, +/+
Pat 11 64/m MDS/AML PB, 10/12 MUD/26/f Flu/Tre/ATG +/−, +/n.d.
Pat 12 71/m hrMDS PB, 10/12 MUD/35/m Flu/Tre/ATG +/−, +/n.d.
Pat 13 60/m MDS/AML PB, full MRD/57/m FluTre −/−, +/+
Pat 14 67/f Post-ET myelofibrosis PB, 10/12 MUD/30/f Flu/Bu3/ATG −/+, +/+
Pat 15 64/f hrAML PB, 11/12 MUD/20/f Flu/Bu3/ATG +/+, +/+
Pat 16 66/m MCL, relapse after autologous Tx PB, 10/12 MUD/34/m Flu/Cy/TBI/ATG +/−, +/n.d.
Pat 17 42/m MDS/AML PB, full MRD/56/f FluTre +/+, +/+
Pat 18 21/f AML, CR2 PB, full MRD/19/m Flu/Bu4 +/+, n.d./n.d.
Pat 19 67/m hrAML PB, 11/12 MUD/24/m Flu/Bu2/ATG +/−, +/n.d.
Pat 20 30/m hrT-ALL PB/ full MRD/33/m Cy/TBI +/+, +/+
  1. Abbreviations: m male, f female, HLA human leukocyte antigen, MUD matched unrelated donor, MRD matched related donor, CMV cytomegalovirus, EBV Ebstein Barr virus, D donor, R recipient, PB peripheral blood stem cells, Tx transplantation, n.d. not determined, hrAML high-risk acute myeloid leukemia, preB-ALL acute pre-B lymphoblastic leukemia, MDS myelodysplastic syndrome, RAEB1 refractory anemia with excess blasts 1, IR intermediate risk, CR2 second complete remission, ET essential thrombocytosis, hrT-ALL high-risk acute T-lymphoblastic leukemia, MCL mantle cell lymphoma
  2. Conditioning regimens: Cy/TBI: cyclophosphamide 120 mg/kg, fractionated total body irradiation12 Gy Cy/TBI/ATG: cyclophosphamide 120 mg/kg, fractionated total body irradiation 12 Gy, antithymocyte globulin 6 mg/kg
  3. Flu/Cy/TBI/ATG: fludarabine 180 mg/m2, cyclophosphamide 60 mg/kg, fractionated total body irradiation 6 Gy, antithymocyte globulin 6 mg/kg
  4. Flu/Tre: fludarabine 150 mg/m2, treosulfan 2.8 g/m2 Flu/Tre/ATG: fludarabine 150 mg/m2, treosulfan 2.8 g/m2, antithymocyte globulin 4 mg/kg Flu/Bu2, (3), (4)/ATG: fludarabine 150 mg/m2, busulfan 6.4 mg/kg, (9.6 mg/kg), (12.8 mg/kg); antithymocyte globulin 4 mg/kg